MHLW Minister Says Pharmaceuticals Companies Should Apologize For Hepatitis C Victims
This article was originally published in PharmAsia News
The compensation package for hepatitis C patients who used contaminated blood products takes effect on January 16. At a press briefing announcing the news, Japan's Minister of Health, Labor and Welfare Yoichi Masuzoe pointed out that the primary responsibility lies with drug makers, and they should reflect on their roles in the contaminations and apologize. "I expect them to take appropriate responsibilities since the drug makers are not included in the basic agreement package," Masuzoe said. He also urged the pharmaceutical companies to work with the government to resolve the problem.Regarding the compensation cost share by the government and drug companies, Masuzoe said drug companies should contribute two-thirds of the cost, and the government should cover one-third, but concrete numbers are still in negotiations. (Click here for more
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.